Find out what made one of these stocks truly skyrocket.
News & Analysis: Aurinia Pharmaceuticals
Aurinia's experimental lupus med hit pay dirt in a large, pivotal-stage trial.
Results of a phase 3 clinical trial are imminent for the biotech.
Traders are feeling bullish after management provides investors with clinical and financial updates.
Shares jump after a Wall Street pro turns bullish.
AUPH earnings call for the period ending December 31, 2018.
It looks like an important patent that could protect its lead candidate is a done deal.
The pharma company bounced around for much of 2018, but there's intriguing potential in the pipeline.
Stock market slides are rarely kind to development-stage biopharma companies. Did October's sell-off create any opportunities for investors?
Steady progress for the company's experimental lupus treatment took an important step forward